JNJ-6640 is an inhibitor targeting mycobacterial PurF (the first enzyme in the de novo purine biosynthesis pathway) with potent anti-tuberculosis activity. JNJ-6640 exhibits bactericidal activity against Mycobacterium tuberculosis in vitro, with an MIC90 of 8.6 nM. JNJ-6640 disrupts de novo purine biosynthesis, inhibits M. tuberculosis DNA replication in vivo. JNJ-6640 exhibits anti-tuberculosis efficacy in acutely infected mice. JNJ-6640 can be used for the study of tuberculosis.

PYO12 is a 3-phenyl-4-phenoxypyrazole type antibacterial compound. PYO12 exhibits selective activity against Gram-positive bacteria with MIC for S. aureus, B. subtilis, S. pneumoniae, and MRSA of 1, 1, 1, and 4 μg/mL respectively. PYO12 has no activity against Gram-negative bacteria. PYO12 can significantly increase bacterial membrane permeability and significantly upregulate cell wall stress-related genes, possibly by binding to the C55-PP part of lipid II. PYO12 shows a concentration-dependent bactericidal effect, has low toxicity to mammalian cells, and does not cause hemolysis. PYO12 can be used to develop new antibiotics targeting bacterial cell wall synthesis.

MC-02479 is a novel cephalosporin. RWJ-54428 has good activity against most of the organisms tested, including methicillin-resistant staphylococci, E. faecalis, and penicillin-resistant pneumococci, and has moderate activity against E. faecium.

BC-1175 (CB-181963) is a novel cephalosporin and antibacterial agent. CB-181963 displays strong binding to altered PBP 2a. CB-181963 demonstrates marked efficacy against MRSA, Klebsiella pneumoniae, Streptococcus pneumoniae, and Escherichia coli.

BAYV-3522 is an orally effective cephalosporin. BAYV-3522 has antibacterial activity against Gram positive bacteria and some respiratory pathogens. BAYV-3522 can be used in the research of infectious conditions.

HMRZ-62 is an antibacterial agent. HMRZ-62 exhibits antibacterial activity against Methicillin-resistant Staphylococcus aureus (MRSA) and Vancomycin-resistant Enterococcus faecalis (VRE).

Pilabactam (ANT3310) is a broad-spectrum covalent Serine β-Lactamase inhibitor, with IC50 values ranging from 1 nM to 175 nM (a panel of Serine β-Lactamase). Pilabactam potentiates activity of β-lactam antibiotics against Carbapenem-Resistant Enterobacterales (CRE) and Acinetobacter baumannii (CRAB). Pilabactam can be used in the research of bacterial infection.

sCNH240 (Compound P1) is an oral active and selective Rv1625c/Cya activator. sCNH240 has significant anti-tuberculosis activity with a MIC90 of 1.24 μM for Mycobacterium tuberculosis (Mtb) H37Rv strain on cholesterol. sCNH240 can be used for tuberculosis treatment research.

8-Br-GTP (tetrasodium) (8-Bromoguanosine-5'-triphosphate (tetrasodium)) is a derivative of the energy substrate – GTP, for protein synthesis and gluconeogenesis. 8-Br-GTP (tetrasodium) inhibits the E. coli GTPase FtsZ with a Ki of 31.8 μM. 8-Br-GTP (tetrasodium) promotes the assembly of porcine brain microtubules.

L 652813 is a quaternary ammonium heterocyclic amino β-lactam compound. L 652813 exhibits inhibitory activity against a broad spectrum of aerobic and anaerobic bacteria in vitro. L 652813 also exhibits good antibacterial activity in a mouse experimental bacteremia model.

FK 089 is an antibacterial Agent. FK 089 can be used for the research of infection.

DV-7751A is a new Fluoroquinolone and antibacterial agent. DV-7751A inhibits the supercoiling activity of DNA gyrases. DV-7751A exhibits antimicrobial activity against Streptococcus pneumonae, Streptococcus pyogenes, and Peptostreptococcus spp. DV-7751A has a rapid bactericidal effect against S. aureus, Escherichia coli, and P. aeruginosa.

E3709 is an antibacterial agent. E3709 exhibits significant inhibitory activity against Gram-positive bacteria, including Staphylococcus aureus (MRSA), Enterococcus faecalis, streptococci, Clostridia, and diphtheroids. E3709 can be used for research related to Gram-positive bacterial infections.

DS21412020 is a fluoroquinolone antibacterial agent. DS21412020 inhibits bacterial DNA gyrase (GyrA) and topoisomerase IV, leading to DNA breaks. DS21412020 exhibits significant activity against Gram-positive bacteria such as Staphylococcus aureus (MIC = 0.006 μg/mL), Streptococcus pneumoniae (MIC = 0.05 μg/mL), and Methicillin)-resistant Staphylococcus aureus (MIC = 0.2 μg/mL), and Gram-negative bacteria such as Escherichia coli (MIC = 0.006 μg/mL) and Pseudomonas aeruginosa (MIC = 0.78 μg/mL). DS21412020 significantly reduces bacterial load in mouse pneumonia and MRSA infection models. DS21412020 can be used in the development of next-generation quinolone antibiotics.

ABT-255 hydrochloride is an orally active anti-bacterial agent. ABT-255 hydrochloride exhibits potent in vitro potency (MIC = 0.016-0.031 μg/mL) against drug-susceptible and Rifampin- or Ethambutol-resistant Mycobacterium tuberculosis. ABT-255 hydrochloride shows efficacy against S. aureus, S. pneumoniae and E. coli and reduces viable counts of drug-resistant Mycobacterium tuberculosis in CF-1 mice. ABT-255 hydrochloride can be used for the study of pulmonary tuberculosis.

AJI-9561 is a benzoxazole derivative produced by Streptomyces sp. AJI-9561 exhibits cytotoxicity and antibacterial activity. AJI-9561 inhibits the proliferation of Jurkat T cells and mouse P388 leukemia cells, with its IC50 being 0.88 and 1.63 μM respectively. AJI-9561 can be used for research on anti-cancer and antibacterial properties.

KY-9 is an antibacterial active compound.

FCE-20696 (hydrochloride) is an orally active immunomodulator. FCE-20696 (hydrochloride) also shows anti-inflammation and anti-infection effects. FCE-20696 (hydrochloride) can be used for the researches of infection, inflammation and immunology, such as adjuvant arthritis.

CP-74667 is a quinolone antibacterial agent. CP-74667 shows high activity against Xanthomonas maltophilia (MIC50 = 1 μg/mL), Staphylococcus spp. (MIC50 = 0.06-0.12 μg/mL) and enterococci (MIC50 = 0.5-4 μg/mL).

E 5065 is an orally active antibacterial agent. E 5065 exhibits potent in vitro activity against Gram-negative microorganisms, Gram-positive cocci, and anaerobes. E 5065 exhibits an MIC90 of 0.5 μg/mL against Clostridium spp. E 5065 provides protection against experimental infections caused by P. aeruginosa.

ML370 is an antibacterial agent. ML370 exerts antibacterial activity by inhibiting the activity of Vibrio cholerae LuxO kinase. ML370 can be used in the research of infectious diseases such as cholera.

ABT-255 free base is an orally active anti-bacterial agent. ABT-255 free base exhibits potent in vitro potency (MIC = 0.016-0.031 μg/mL) against drug-susceptible and Rifampin- or Ethambutol-resistant Mycobacterium tuberculosis. ABT-255 free base shows efficacy against S. aureus, S. pneumoniae and E. coli and reduces viable counts of drug-resistant Mycobacterium tuberculosis in CF-1 mice. ABT-255 free base can be used for the study of pulmonary tuberculosis.

KP 736 (sodium) is a broad-spectrum antibacterial agent. KP 736 (sodium) exhibits excellent broad-spectrum anti Gram negative bacterial activity in vitro, especially effective against Pseudomonas aeruginosa and multiple drug-resistant bacteria. KP 736 (sodium) can be used for research on bacterial infections.

Bacillibactin (Corynebactin) is a cyclic tricatecholate siderophore. Bacillibactin’s primary function is to facilitate bacterial iron acquisition by chelating iron ions (Fe3+) from the environment, thereby aiding bacterial survival under iron-limited conditions. Bacillibactin exhibits direct antimicrobial activity, such as inhibition of the growth of the producing bacteria Pseudomonas aeruginosa and Aeromonas veronae, as well as plant pathogens such as Pseudomonas syringae.Bacillibactin can be used in antibacterial and antifungal research.

LY 255262 is an antibacterial agent. LY 255262 exhibits potent inhibitory effects against a variety of Gram-positive and Gram-negative bacteria in vitro. LY 255262 has MIC values of 64, 0.25, 0.5, 0.25, 0.25, 1, and 1 μg/mL for Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenza, Escherichia coli, Klebsiella, Enterobacter aerogenes, and Serratia, respectively. LY 255262 has a relatively weak inhibitory effect on Pseudomonas (MIC >128 μg/mL). LY 255262 can be used in antibacterial research.

MC-207110 is a broad-spectrum efflux pump inhibitor. MC-207110 is active against all three known Mex efflux pumps from P. aeruginosa and their close Escherichia coli efflux pump homolog (AcrAB-TolC). MC-207110 can decrease the intrinsic resistance of P. aeruginosa to fluoroquinolones. MC-207110 can be used for the research of infection .

MC-04124 is an efflux pump inhibitor. MC-04124 significantly enhances the activity of Levofloxacin against Pseudomonas aeruginosa.

NLCQ-1 (NSC 709257) is an orally active antibacterial agent targeting dormant Mycobacterium tuberculosis. NLCQ-1 is promising for research of tuberculosis.

HC2210 has an antibacterial effect against Mycobacterium abscessus (Mab) (EC50: 0.72 µM). HC2210 modulates the expression of Mab genes related to oxidative stress and lipid metabolism. HC2210 can be used in the study of Mab infection.

AR-102 has inhibitory activity towards Staphylococcus aureus. AR-102 exhibits a competitive potent inhibition of the F98Y mutant DHFR (Ki = 0.22 nM). AR-102 has been determined as ternary complex with NADPH in both wild-type S. aureus DHFR and the TMP-resistant F98Y mutant enzyme.